C Ngô1, C Brugier2, C Plancher3, A de la Rochefordière4, S Alran2, J G Féron2, C Malhaire5, S Scholl6, X Sastre7, R Rouzier2, V Fourchotte2. 1. Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. Electronic address: nphuongvi@hotmail.com. 2. Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. 3. Department of Biostatistics, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. 4. Department of Radiotherapy, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. 5. Department of Medical Imaging, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. 6. Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. 7. Department of Pathology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
Abstract
OBJECTIVE: To compare the clinic-pathologic variables and the prognosis of endometrial cancer in patients with and without previous breast cancer, with and without Tamoxifen. METHODS: We analyzed patients treated for an endometrial carcinoma from 1994 to 2004: patients without breast cancer (group 1), patients with a previous breast cancer without tamoxifen (group 2) and patients treated for breast cancer with tamoxifen (group 3). Survival rates were calculated according to Kaplan-Meier method and compared using a Log rank test, multivariate analysis was performed with a Cox regression model. RESULTS: 363 patients were analyzed. 80 patients had a previous history of breast cancer (43 received tamoxifen). Although it was not statistically significant, more carcinosarcomas were observed in patients in group 3 than patients in groups 1 and 2 (11.7% versus 4.2% and 5.4% respectively, p = 0.17).) Median follow-up was 87 months [2-185]. 5-year overall survival rate was respectively in groups 1, 2 and 3: 82%, 73.2%, and 61% (p = 0.0006). 5-year local relapse-free survival rate was respectively: 95.9%, 93.1% and 82.5% (p = 0.02). In multivariate analysis, factors affecting overall survival rate were: age ≥65 ans (HR 3.62, p < 0.0001), FIGO stage (HR 3.33 p < 0.0001 for locally advanced stage versus early stage, HR 8.87 p = 0.03 for distant extension versus early stage), and group 3 (HR 2.83 p < 0.001 versus group 1). CONCLUSION: Patients with endometrial cancer previously treated for breast cancer show a worse prognostic, particularly if they reveived tamoxifen.
OBJECTIVE: To compare the clinic-pathologic variables and the prognosis of endometrial cancer in patients with and without previous breast cancer, with and without Tamoxifen. METHODS: We analyzed patients treated for an endometrial carcinoma from 1994 to 2004: patients without breast cancer (group 1), patients with a previous breast cancer without tamoxifen (group 2) and patients treated for breast cancer with tamoxifen (group 3). Survival rates were calculated according to Kaplan-Meier method and compared using a Log rank test, multivariate analysis was performed with a Cox regression model. RESULTS: 363 patients were analyzed. 80 patients had a previous history of breast cancer (43 received tamoxifen). Although it was not statistically significant, more carcinosarcomas were observed in patients in group 3 than patients in groups 1 and 2 (11.7% versus 4.2% and 5.4% respectively, p = 0.17).) Median follow-up was 87 months [2-185]. 5-year overall survival rate was respectively in groups 1, 2 and 3: 82%, 73.2%, and 61% (p = 0.0006). 5-year local relapse-free survival rate was respectively: 95.9%, 93.1% and 82.5% (p = 0.02). In multivariate analysis, factors affecting overall survival rate were: age ≥65 ans (HR 3.62, p < 0.0001), FIGO stage (HR 3.33 p < 0.0001 for locally advanced stage versus early stage, HR 8.87 p = 0.03 for distant extension versus early stage), and group 3 (HR 2.83 p < 0.001 versus group 1). CONCLUSION:Patients with endometrial cancer previously treated for breast cancer show a worse prognostic, particularly if they reveived tamoxifen.
Authors: Jieqiong Liu; Wen Jiang; Kai Mao; Yi An; Fengxi Su; Betty Y S Kim; Qiang Liu; Lisa K Jacobs Journal: Breast Cancer Res Treat Date: 2015-03-13 Impact factor: 4.872
Authors: Sharon E Johnatty; Colin J R Stewart; Deborah Smith; Daniel Buchanan; Yee Leung; Martin K Oehler; Alison Brand; Penelope M Webb; Amanda B Spurdle Journal: Cancer Med Date: 2018-11-28 Impact factor: 4.452